Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 25,760

Document Document Title
WO/2021/072353A1
Disclosed herein are CMV-specific CARs. In some embodiments, the present invention is directed to a method of treating, reducing, or inhibiting an infection by a cytomegalovirus in a subject, which comprises administering to the subject ...  
WO/2021/068108A1
The present invention provides a fusion protein, comprising an antigen-binding domain, a transmembrane domain, and a costimulatory signaling region. The antigen-binding domain can specifically bind to a tumor-specific antigen, that is an...  
WO/2021/037290A3
Provided is a fusion polypeptide, containing domains N-Acetyl-Ser-Asp-Lys-Pro, Ser-Asp-Lys-Pro, Thr-Ser-Leu-Asp-Ala-Ser-Ile-Ile-Trp-Ala-Met-Met-Gln-Asn and Leu-Ser-Lys-Leu, or any mutated amino acids in the described domains, the domains...  
WO/2021/068080A1
Described herein is an immunogenic fusion protein comprising: an immunogenic peptide or an immunogenic variant thereof, the immunogenic peptide comprising the following motifs: - KQPAa; QPAKa; PAKQa; or AKQPa; - NPDPb; PNPDb; DPNPb; or P...  
WO/2021/068074A1
Described herein are methods and compositions for selective activation of cells using variant cytokine receptor and cytokine pairs, wherein the cytokine receptors comprise an extracellular domain (ECD) of granulocyte-colony stimulating f...  
WO/2021/072250A1
Provided are recombinant polypeptides that comprise a protein of interest, a protein localization tag, and a protease cleavage site disposed between the protein of interest and the protein localization tag. In certain embodiments, the re...  
WO/2021/068752A1
Provided are a fusion protein and the medical use thereof. The fusion protein is prepared by fusing a human interleukin-10 (IL-10) with an Fc fragment of an immunoglobulin IgG via a linker peptide. The Fc fragment is the Fc fragment of h...  
WO/2021/068068A1
Described herein are chimeric receptors comprising G-CSFR extracellular domains and the intracellular domains of various multi-subunit cytokine receptors for selective activation of cytokine signaling in cells of interest. In certain asp...  
WO/2021/068072A1
Disclosed herein is a targeted tumour-infiltrating bacteriophage. The bacteriophage is engineered to present an epidermal growth factor receptor (EGFR)-binding moiety on the bacteriophage cell surface. The EGFR-binding moiety is capable ...  
WO/2021/034958A3
The present disclosure provides devices comprising a therapeutic agent bound to a printed three-dimensional structure. The printed three-dimensional structure comprises about 50% to about 100% by weight ceramic and about 0% to about 50% ...  
WO/2021/068986A1
Provided in the present invention is a use of novel GLP-1 fatty acid-modified or non-modified dimers of different configurations for a pancreas protecting or glucose reducing effect in treating type 2 diabetes. The dimers of the present ...  
WO/2021/046398A3
Described herein are peptides, compositions, and method of treating measles or HIV infection with antiviral peptide conjugates comprising a fusion inhibitory peptide (FIP) conjugated to a C-terminal heptad repeat (HRC) peptide. Also desc...  
WO/2021/067233A1
Provided herein are 2'-O-methyl 3'phosphorothioate (MS)-modified synthetic nucleic acid molecules (single guide RNAs (sgRNAs)) in combination with a base editor as a ribonucleoprotein (RNP) complex for an electroporation-based ex vivo ta...  
WO/2021/063313A1
Disclosed are an Fc variant that has an altered effector function and a fusion protein thereof. An Fc region of the Fc variant comprises one or more amino acid changes, and has an altered effector function; further, disclosed are a fusio...  
WO/2021/067571A1
The present disclosure relates, in one aspect, to the identification of certain peptides that allow for transport of a solid particle across the air-blood barrier in the lungs. In certain embodiments, the solid particle comprises any sor...  
WO/2020/257288A3
The present invention provides isolated T cell receptors (TCRs) that specifically bind to an H LA-displayed cancer testis antigen Melanoma-Associated Antigen A4 (MAGE-A4) peptide, as well as therapeutic and diagnostic methods of using th...  
WO/2021/063350A1
A fusion protein, which comprises human TGFBRII or a fragment thereof and an antibody or antigen binding fragment thereof that specifically binds to PD-L1. Further provided is an application of the fusion protein in the preparation of a ...  
WO/2021/063352A1
Provided is an anti-PD-L1 antigen binding protein, capable of binding to primate-derived PD-L1 with a KD value of 1×10-8M or less. The antigen binding protein can block the binding of PD-1 and CD80 to PD-L1, stimulate the secretion of c...  
WO/2021/064068A1
Disclosed are fusion polypeptides comprising at least two carbohydrate binding modules (CBMs), wherein the polypeptide has carbohydrate binding activity. Also disclosed is the use of such polypeptides for reducing the wrinkles in laundry...  
WO/2021/063331A1
The present disclosure relates to use of a combination of a EZH2 inhibitor and a TGF-β receptor-containing fusion protein in preparation of drugs for treating tumors. Specifically, a EZH2 inhibitor involved in the present disclosure is ...  
WO/2021/042062A3
Engineered bifunctional adenine and cytosine base editor (BACE) variants that enable expanded amino acid modifications and methods of using the same. Described herein are fusion proteins containing adenosine deaminases, cytidine deaminas...  
WO/2021/062155A1
Provided are compositions, including products of manufacture and kits, and methods, for remotely-controlled and non-invasive manipulation of intracellular nucleic acid expression, genetic processes, function and activity in live cells su...  
WO/2021/062181A1
The present invention relates, in part, to pegylated chimeric proteins comprising one or more targeting moieties, linkers, and one or more signaling moieties, or variants thereof, and their use as therapeutic agents.  
WO/2021/057451A1
An antibody fusion protein, a preparation method therefor and use thereof against anti-tumor. The antibody fusion protein comprises an anti-HER2 monoclonal antibody IgG and a D2 domain of a VEGFR1, the D2 domain of the VEGFR1 is connecte...  
WO/2021/056302A1
The present invention provides methods and compositions for modifying a target site in the genome of a cell. Fusion proteins including one or more DNA binding domains and one or more DNA modifying domains connected by improved linker seq...  
WO/2021/057866A1
An antigen binding protein that targets BCMA, in particular a chimeric antigen receptor comprising the antigen binding protein, and an application thereof. The chimeric antigen receptor comprises an extracellular domain that targets BCMA...  
WO/2021/062184A1
The present invention relates, in part, to agents that bind PD-L1 and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the PD-L1 targeting moiety and their us...  
WO/2021/057003A1
A Schistosoma haematobium recombinant fusion protein ShSAP and an application thereof in the immunodiagnosis of schistosomiasis. The Schistosoma haematobium recombinant fusion protein ShSAP can undergo large-scale standardized mass produ...  
WO/2021/062374A1
The present disclosure provides, in part, peptide self-assemblies that are made into tablet form and methods of making and using the same. In some embodiments, the disclosure provides methods and formulations for a tabletized form of a v...  
WO/2021/034418A3
Cell penetrating peptides that target many cells types including cells of the retina and cornea with high efficiency are provided herein. These peptides can be used to deliver cargo molecules across a plasma membrane, without the need fo...  
WO/2021/057822A1
The present invention provides anti-ROR1 antibodies and methods of using said antibodies. The anti-ROR1 antibodies described herein are useful for the diagnosis and treatment of diseases associated with aberrant expression of ROR1.  
WO/2021/061791A1
The present disclosure generally relates to, inter alia, a new class of chimeric Notch receptors containing a synthetic zinc finger transcriptional effector (synZTE) module, engineered to modulate gene expression and cellular activities ...  
WO/2021/061778A1
The present invention relates to compositions and methods comprising a chimeric antigen receptor (CAR) capable of binding fibroblast activation protein (TAP) for use in treating diseases, disorders or conditions associated with the expre...  
WO/2021/057823A1
The present invention provides ROR1 specific chimeric antigen receptors (CAR) and their therapeutic use. The CAR comprises a signal peptide, a ROR1 antigen binding domain, a hinge, a transmembrane domain, a co-stimulatory domain and an i...  
WO/2021/052152A1
The present invention relates to the technical field of biomedicine engineering, and provides a composition related to soluble dimer immunoadhesin and a method. The dimeric immunoadhesin comprises a dimerized first and second polypeptide...  
WO/2021/054867A1
The present invention relates to an immunocytokine comprising a heterodimeric protein complex based on IL-15/IL-15Rα, and to the use thereof as a therapeutic agent, more particularly as a drug for treating cancer and autoimmune diseases...  
WO/2021/055372A1
The present disclosure provides fusion proteins with improved signaling properties. Disclosed embodiments include fusion proteins that comprise an extracellular component comprising a target-binding domain, a transmembrane domain, and an...  
WO/2021/055816A1
Provided herein are PD-L1 binding molecules comprising or conjugated to a toxin, e.g. a Shiga toxin A Subunit derived polypeptide. In some embodiments, the PD-L1 binding molecules are cytotoxic. In some embodiments, the PD-L1 binding mol...  
WO/2021/052349A1
Provided are a GIPR antibody and a fusion protein between same and GLP-1, and a pharmaceutical composition thereof. Further provided is a method for using a GIPR antibody and a fusion protein between same and GLP-1 to treat, prevent or i...  
WO/2021/031839A9
Provide are a targeted polypeptide-modified drug-loaded lipoprotein nano-drug delivery system, and preparation and application thereof. The drug delivery system comprises a lipid, an apolipoprotein, a loaded drug, and a targeted polypept...  
WO/2021/051195A1
Described herein is a chimeric costimulatory receptor (CCR) molecule having an extracellular domain of a Tumor Necrosis Factor Superfamily member, a transmembrane domain and a cytosolic costimulatory signaling domain from a Tumor Necrosi...  
WO/2021/051661A1
A recombinant canine PD-1 fusion protein and a preparation method therefor and an application thereof. The fusion protein is formed by directly or indirectly linking the extracellular domain of a canine PD-1 protein or the mutant of the ...  
WO/2021/055942A1
Chimeric antigen receptor T cell (CARTs) compositions and methods of their use are provided. One embodiment provides a chimeric antigen receptor T cell composition including 8F8 chimeric antigen receptor T cells. Another embodiment provi...  
WO/2021/046652A1
Disclosed herein are uses of a polypeptide comprising NIMoEsh to treat a disease or condition associated with acute myocardial infarction (AMI) in a subject in need thereof, of a polypeptide comprising NIMoEsh to restore heart function a...  
WO/2021/049606A1
The present invention addresses the problem of providing: a DcR3 variant that has the binding activity (preferably neutralizing activity) of DcR3 to ligands and that exhibits improved in vivo kinetics and/or reduces the amount of generat...  
WO/2021/049634A1
Provided are: a nucleic acid that includes a nucleic acid sequence for encoding a signal sequence and a nucleic acid sequence for encoding a chimeric protein including at least a portion of ion transport receptor rhodopsin and at least a...  
WO/2021/046653A1
Provided are antibodies that specifically bind Vaccinia Virus (VV) A56 or B5 antigen. Also provided are fusion proteins and conjugates that comprise the antibodies. Pharmaceutical compositions and kits that comprise the antibodies, fusio...  
WO/2021/050722A1
The present disclosure describes a GnRH therapeutic for neutralizing GnRH levels in subjects which can reduce testosterone levels to attenuate or eliminate prostate cancer cell growth and/or metastasis. The therapeutic is produced synthe...  
WO/2021/048724A1
Provided is a nucleic acid encoding a chimeric CD3 fusion protein and an anti-CD3 based bispecific T cell activator (BiTA) element. Also provided are vectors, engineered immune cells comprising the nucleic acid, the usage thereof and met...  
WO/2021/026254A3
The present disclosure relates to protein sequences which can be used to generate factor Xa proteins and derivatives thereof. The protein sequences include a factor Xa light chain portion, a heavy chain catalytic domain portion, and an a...  

Matches 1 - 50 out of 25,760